Concord Biotech share price
NSE: CONCORDBIOBSE: 543960Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,375.30.
28 Oct: open ₹1,319.90, high ₹1,333.00, low ₹1,262.60
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹13,271 Cr496th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 46.98
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.39
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.60%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 14.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,80,22234.2% delivered
About Concord Biotech
Concord Biotech Limited develops and manufactures fermentation-based active pharmaceutical ingredients (APIs), finished formulations, and contract development and manufacturing services (CDMO). It serves more than 300 customers in over 70 countries. Its CDMO and contract research services support pharmaceutical innovators and generic manufacturers. Its products cover immunosuppressants, oncology, anti-bacterial and anti-fungal therapies.
The business has two main lines. The API portfolio has more than 30 fermentation-based products. The formulations line covers oral solid dosage products and injectable medicines made at its Valthera facility. Formulations are sold largely in India through government and corporate hospitals and distribution networks. In the US and in emerging markets in Asia, Africa and Latin America, the company sells through distributors.
The registered office and a plant are at Trasad Road, Dholka, in Ahmedabad district. Unit I at Dholka is the API facility, Unit II is a formulation facility, and Unit IV at Valthera makes injectables. Its facilities have been inspected by regulators including the USFDA, EU GMP and PMDA (Japan). A team of 180 scientists works on research and development.
It was incorporated in 1984. It has a wholly owned subsidiary, Concord Lifegen Limited, set up to strengthen marketing, sales and distribution. It also holds a 75% stake in Stellon Biotech Inc., a United States subsidiary that markets and distributes its products.
Sudhir Vaid, the Chairman and Managing Director, and his son Ankur Vaid, the Joint Managing Director and Chief Executive Officer, are the company's promoters. A promoter is the person or group that set up a company or controls it.
Written from the annual report for the year to Mar 2026, filed 7 Jul 2026 and the investor presentation.
Sources for 26 statements, each with its page
- Develops and manufactures fermentation-based APIs. Annual report, page 6
- Also makes finished formulations and offers contract development and manufacturing services. Annual report, page 6
- Serves more than 300 customers. Annual report, page 6
- Customers are in over 70 countries. Annual report, page 6
- CDMO and contract research services support pharmaceutical innovators and generic manufacturers. Annual report, page 6
- Therapeutic areas: immunosuppressants, oncology, anti-bacterial, anti-fungal. Annual report, page 6
- API portfolio has more than 30 fermentation-based products. Annual report, page 12
- Formulations include oral solid dosage products. Annual report, page 27
- Injectable facility is at Valthera. Annual report, page 34
- Formulations are sold largely in India through government and corporate hospitals and distribution networks. Annual report, page 17
- In the US and emerging markets in Asia, Africa and Latin America it relies on distributors. Annual report, page 17
- Registered office and a plant are at Trasad Road, Dholka, Ahmedabad district. Annual report, page 1
- Unit I is the Dholka API facility. Annual report, page 34
- Unit II is a formulation facility. Annual report, page 20
- Facilities inspected by USFDA, EU GMP and PMDA (Japan). Annual report, page 13
- Team of 180 scientists. Annual report, page 17
- Incorporated in 1984 (year in the CIN). Annual report, page 1
- Concord Lifegen Limited is a wholly owned subsidiary. Annual report, page 50
- Lifegen was set up to strengthen marketing, sales and distribution. Annual report, page 50
- Holds a 75% stake in Stellon Biotech Inc., a US subsidiary. Annual report, page 50
- Stellon Biotech serves for marketing and distribution of the company's products. Annual report, page 50
- Sudhir Vaid is a promoter. Annual report, page 66
- Ankur Vaid is a promoter. Annual report, page 66
- Ankur Vaid is the son of Sudhir Vaid. Annual report, page 66
- Sudhir Vaid is Chairman and Managing Director. Annual report, page 43
- Ankur Vaid is Joint Managing Director and CEO. Annual report, page 43
Results
Consolidated; ₹ crore.Concord Biotech quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +4.0%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −12.8%
Quarter to Sep 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹309 Crup 20.03%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹70 Crup 20.58%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 22.5%
Revenue by quarter
Net profit by quarter, a loss in red
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 244 | 430 | 204 | 247 | 278 | 326 | 257 | 309 |
| Net profit | 76 | 140 | 44 | 63 | 64 | 88 | 58 | 70 |
| Net margin | 31.1% | 32.7% | 21.6% | 25.5% | 22.9% | 27.1% | 22.4% | 22.5% |
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1,055 Crdown 12.10%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹259 Crdown 30.25%
- Net margin
- 24.6%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue | 1,017 | 1,200 | 1,055 |
| Net profit | 308 | 372 | 259 |
| Net margin | 30.3% | 31.0% | 24.6% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.Concord Biotech PE ratio and valuation
At or below today's level on 28% of 599 trading days since May 2024.
At or below today's level on 5% of 727 trading days since Nov 2023.
At or below today's level on 67% of 694 trading days over the last 3 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −38.7% | −30.2% | −13.1% | 0.7% |
Mutual fund holdings
58 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 43 of the 45 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 58 funds holding Concord Biotech
- AddedAdded. Funds that held more shares than at the end of the month before.
- 17
- CutCut. Funds that held fewer shares than at the end of the month before.
- 28
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 13
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 2
| Fund | |||
|---|---|---|---|
 DSP Small Cap FundDSP Mutual Fund | 26,19,839 | 1.68% | ₹359.9 Cr |
 SBI Healthcare Opportunities FundSBI Mutual Fund | 9,60,000 | 2.25% | ₹131.9 Cr |
| DSP Healthcare FundDSP Mutual Fund | 7,35,820 | 2.70% | ₹101.1 Cr |
 Edelweiss Small Cap FundEdelweiss Mutual Fund | 5,64,819 | 1.11% | ₹77.6 Cr |
 Helios Mid Cap FundHelios Mutual Fund | 1,35,043 | 0.79% | ₹18.5 Cr |
| SBI Balanced Hybrid FundSBI Mutual Fund | 1,20,000 | 0.83% | ₹16.5 Cr |
 ITI Flexi Cap FundITI Mutual Fund | 1,17,004 | 1.01% | ₹16.1 Cr |
 Nippon India Pharma FundNippon India Mutual Fund | 1,11,738 | 0.17% | ₹15.3 Cr |
| Helios Small Cap FundHelios Mutual Fund | 1,04,509 | 0.76% | ₹14.4 Cr |
 Baroda BNP Paribas Innovation FundBaroda BNP Paribas Mutual Fund | 80,000 | 1.28% | ₹11.0 Cr |
Concord Biotech competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Concord Biotech in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Alembic PharmaceuticalsAPLLTD | 15,387 | 22.26 | 2.71 | +14.1% | +14.6% | 12.7% | 11.8% | 1.53% |
 Jubilant PharmovaJUBLPHARMA | 15,035 | 42.70 | 2.12 | +16.3% | −23.5% | 5.3% | 7.3% | 0.53% |
 Marksans PharmaMARKSANS | 13,831 | 26.76 | 4.57 | – | – | 17.1% | 19.9% | 0.29% |
 CORONA RemediesCORONA | 13,459 | 67.62 | 18.02 | – | – | 26.6% | 30.9% | 0.45% |
 Akums Drugs and PharmaceuticalsAKUMS | 11,375 | 38.99 | 3.43 | +9.2% | −14.6% | 9.2% | 12.0% | 0.42% |
 Viyash ScientificVIYASH | 10,025 | – | 3.44 | +96.5% | – | – | 11.2% | 0.00% |
 Strides Pharma ScienceSTAR | 10,006 | 16.31 | 3.22 | +7.3% | – | 21.7% | 15.1% | 0.46% |
 Blue Jet HealthcareBLUEJET | 9,802 | 41.73 | – | −27.5% | −34.5% | 18.8% | 18.1% | 0.23% |
Dividends
Per share, by the year it was paid for, and the latest payments.Concord Biotech dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossary| Ex-date | Type | Per share |
|---|---|---|
| 24 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹7.55 |
| 3 Sep 2025 | Final | ₹10.70 |
| 21 Jun 2024 | Final | ₹8.75 |
Latest announcements
Routine notices left out.Concord Biotech announcements
Oct 2026
28 Oct · Analysts
27 Oct · Corporate action
27 Oct · Results
23 Oct · Analysts
22 Oct · Board meeting
Concord Biotech share price by year
Each calendar year to 2025.Concord Biotech share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,345.60 | −39.1% | 2,345.60 | 1,329.00 |
| 2024 | 2,210.75 | +50.2% | 2,601.10 | 1,366.65 |
| 2023 | 1,471.80 | – | 1,506.10 | 942.80 |
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 1,309.30 | 1,393.90 | 1,297.70 | 1,375.30 | 1,355.29 | 1,57,342 | 43.0% |
| 26 Oct 2026 | 1,225.00 | 1,325.00 | 1,225.00 | 1,311.20 | 1,290.90 | 1,85,480 | 25.5% |
| 23 Oct 2026 | 1,270.50 | 1,279.70 | 1,212.50 | 1,229.30 | 1,228.68 | 96,706 | 53.4% |
| 22 Oct 2026 | 1,270.00 | 1,308.90 | 1,252.90 | 1,270.70 | 1,276.28 | 93,347 | 39.0% |
| 21 Oct 2026 | 1,266.80 | 1,284.00 | 1,251.00 | 1,270.00 | 1,263.95 | 83,316 | 49.6% |
| 19 Oct 2026 | 1,350.00 | 1,350.00 | 1,276.10 | 1,285.80 | 1,301.25 | 79,842 | 56.9% |
| 16 Oct 2026 | 1,362.90 | 1,366.80 | 1,332.00 | 1,339.00 | 1,342.77 | 45,381 | 55.4% |
| 15 Oct 2026 | 1,390.80 | 1,394.90 | 1,350.00 | 1,353.30 | 1,361.04 | 35,984 | 45.7% |
| 14 Oct 2026 | 1,378.80 | 1,395.60 | 1,372.10 | 1,382.10 | 1,384.17 | 63,724 | 57.0% |
Company details
- NSE symbol
- CONCORDBIO
- BSE code
- 543960
- ISIN
- INE338H01029
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.concordbiotech.com
- CIN
- L24230GJ1984PLC007440
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1984
- Registered office
- 1482-86, Trasad Road, Dholka, Ahmedabad 382225, Gujarat
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments